164 related articles for article (PubMed ID: 26548975)
1. Intra-tumor distribution of PEGylated liposome upon repeated injection: No possession by prior dose.
Nakamura H; Abu Lila AS; Nishio M; Tanaka M; Ando H; Kiwada H; Ishida T
J Control Release; 2015 Dec; 220(Pt A):406-413. PubMed ID: 26548975
[TBL] [Abstract][Full Text] [Related]
2. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
[TBL] [Abstract][Full Text] [Related]
3. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X-ray Fluorescence Spectrometry.
Ando H; Abu Lila AS; Tanaka M; Doi Y; Terada Y; Yagi N; Shimizu T; Okuhira K; Ishima Y; Ishida T
Mol Pharm; 2018 Feb; 15(2):403-409. PubMed ID: 29287147
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
Abu Lila AS; Okada T; Doi Y; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Apr; 426(1-2):263-270. PubMed ID: 22310465
[TBL] [Abstract][Full Text] [Related]
6. Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing.
Doi Y; Abu Lila AS; Matsumoto H; Okada T; Shimizu T; Ishida T
Int J Nanomedicine; 2016; 11():5573-5582. PubMed ID: 27822036
[TBL] [Abstract][Full Text] [Related]
7. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
[TBL] [Abstract][Full Text] [Related]
8. Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application.
Nagao A; Abu Lila AS; Ishida T; Kiwada H
Int J Pharm; 2013 Jan; 441(1-2):395-401. PubMed ID: 23174409
[TBL] [Abstract][Full Text] [Related]
9. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
10. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.
Abu Lila AS; Doi Y; Nakamura K; Ishida T; Kiwada H
J Control Release; 2010 Mar; 142(2):167-73. PubMed ID: 19861140
[TBL] [Abstract][Full Text] [Related]
11. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
Suzuki R; Takizawa T; Kuwata Y; Mutoh M; Ishiguro N; Utoguchi N; Shinohara A; Eriguchi M; Yanagie H; Maruyama K
Int J Pharm; 2008 Jan; 346(1-2):143-50. PubMed ID: 17640835
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
13. Accelerated clearance of a second injection of PEGylated liposomes in mice.
Ishida T; Masuda K; Ichikawa T; Ichihara M; Irimura K; Kiwada H
Int J Pharm; 2003 Apr; 255(1-2):167-74. PubMed ID: 12672612
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of liposomal l-OHP and PEGylated TS shRNA-lipoplex: A novel approach to enhance anti-tumor efficacy and reduce the immunogenic response to RNAi molecules.
Alaaeldin E; Abu Lila AS; Ando H; Fukushima M; Huang CL; Wada H; Sarhan HA; Khaled KA; Ishida T
J Control Release; 2017 Jun; 255():210-217. PubMed ID: 28461099
[TBL] [Abstract][Full Text] [Related]
15. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
16. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
[TBL] [Abstract][Full Text] [Related]
17. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy.
Yang Q; Ma Y; Zhao Y; She Z; Wang L; Li J; Wang C; Deng Y
Int J Nanomedicine; 2013; 8():1257-68. PubMed ID: 23576868
[TBL] [Abstract][Full Text] [Related]
18. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes.
Koide H; Asai T; Hatanaka K; Akai S; Ishii T; Kenjo E; Ishida T; Kiwada H; Tsukada H; Oku N
Int J Pharm; 2010 Jun; 392(1-2):218-23. PubMed ID: 20227473
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of poly(hydroxyethyl-l-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration.
Romberg B; Oussoren C; Snel CJ; Carstens MG; Hennink WE; Storm G
Biochim Biophys Acta; 2007 Mar; 1768(3):737-43. PubMed ID: 17223070
[TBL] [Abstract][Full Text] [Related]
20. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]